Advanced Search

Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2012 April;67(2) > Minerva Chirurgica 2012 April;67(2):165-73

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA CHIRURGICA

A Journal on Surgery

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,877

Frequency: Bi-Monthly

ISSN 0026-4733

Online ISSN 1827-1626

 

Minerva Chirurgica 2012 April;67(2):165-73

    ORIGINAL ARTICLES

Gastrointestinal stromal tumors treatment in the Imatinib era. The role of fair indication

Vendettuoli M., Pironi D., Pontone S., Panarese A., La Gioia G., Arcieri S., Romani A. M., Palazzini G., Filippini A.

Department of Surgical Sciences, La Sapienza University, Rome, Italy

AIM: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery remains the elective treatment. We retrospectively compared two group of patients, who underwent surgery for GIST before and after Imatinib advent in order to analyze the recurrence and survival rate.
METHODS: Two patient groups who underwent surgery for GIST, from January 1997 to December 2002 (Pre-Imatinib group) and from January 2003 to December 2008 (Post-Imatinib group) were compared. Patients were evaluated on the base of gender, age, clinical manifestations, primary location and metastasis positivity, tumor size, mitotic index, immunoreactivity for CD117 and the outcome, including date of death.
RESULTS: In the Pre-IM group only one patient died for prostate cancer, 12 months after operation, the other died because of GIST with a 24.6 months of median survival rate (range 15-51). In the remaining 12 patients the median follow up period was 55 months (range 6-152 months). In the Post-IM group the mean follow up was 50.7 months (range 26-74) and they are still being assessed for oncological as well as surgical treatment.
CONCLUSION: Early diagnosis and radical resection remain the standard of cure for GISTs. To date, the use of Imatinib lead to its utilization as adjuvant and neo-adjuvant therapy in adults. Our experience suggests that there is a correlation between the mutational status of KIT and clinical outcome. These aspects should be explored for targeted therapy that can effectively combine biological therapy to surgery.

language: English


FULL TEXT  REPRINTS

top of page